patent.fyi
Applications  /  US 2026/0355172
United States Patent Application Publication

US 2026/0355172 A1

Published
Nov 12, 2026
Filed
Oct 23, 2023
Earliest date on the face
Oct 26, 2022
Classification
A61K 31/4545
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Selection by mismatch repair

What ifWhat if tumor selection used mismatch repair protein loss?
Claim language“identifying the cancer to be a BRCA mutation cancer”

Immunohistochemistry measures four mismatch repair proteins in a fixed tumor section. Loss of tumor nuclear staining with retained staining in internal control cells identifies tumors for a mismatch repair deficiency treatment pathway.

1.1Selection by estrogen receptor

What ifWhat if breast tumor selection used estrogen receptor expression?
Claim language“a BRCA wild type cancer having a homologous recombination deficiency”

A pathologist uses immunohistochemistry to measure the percentage of invasive tumor cell nuclei that stain for estrogen receptor. The receptor result guides selection for endocrine therapy, which reduces estrogen production or blocks receptor signaling.

1.1Selection by platinum response

What ifWhat if ovarian cancer selection used response to platinum chemotherapy?
Claim language“identifying the cancer to be a BRCA mutation cancer”

Serial imaging measures target lesions before and after platinum chemotherapy. A documented complete or partial response serves as the entry criterion for a response-based maintenance pathway.

1.2Microtubule stabilization during mitosis

What ifWhat if a microtubule stabilizer supplied the mitotic effect in a combination with a PARP inhibitor?
Claim language“an Aurora A inhibitor”

In a tumor cell assay, a taxane binds polymerized tubulin and suppresses microtubule dynamics, disrupting chromosome segregation. A PARP inhibitor supplies the DNA repair perturbation, and a clonogenic assay measures survival after combined exposure.

1.2Single agent platinum chemotherapy

What ifWhat if treatment used a single platinum compound?
Claim language“a pharmaceutical combination comprising”

An intravenous platinum compound forms covalent DNA adducts that impede replication. In a single-agent ovarian cancer regimen, the target systemic exposure and an estimate of renal filtration determine the infusion dose.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Component substitution

Functional repair testing with RAD51 foci

A RAD51 nuclear focus assay replaces genomic scar scoring in the homologous recombination deficiency assessment for BRCA wild-type samples. A tumor section is stained for RAD51, geminin, and phosphorylated histone H2AX, and image analysis counts RAD51 foci in geminin-positive tumor nuclei with evidence of DNA damage. A sample enters the paired inhibitor workflow when it meets the assay's quality criteria and its RAD51 focus score falls below the assay threshold.

Automated or data-driven variant

Automated classification of tumor eligibility

A rules engine reads BRCA variant classifications, the homologous recombination deficiency result, and assay quality flags from the same tumor report. It classifies a sample as eligible when the report identifies a pathogenic BRCA variant or explicitly records both wild-type BRCA and a positive deficiency result. The engine routes missing, indeterminate, or conflicting results for review and records the supporting report fields with each classification.

Specific version of a part

Paired tumor and blood sequencing

A hybrid capture panel sequences the coding exons and splice junctions of both BRCA genes in tumor DNA and matched blood DNA. Comparison of the two samples distinguishes tumor-specific variants from inherited variants and supports identification of pathogenic alterations.

Genomic scar scoring

Tumor sequencing establishes BRCA status and measures allele-specific copy number across the genome. A composite score combines regions of loss of heterozygosity, telomeric allelic imbalance, and large-scale chromosomal transitions to classify homologous recombination deficiency in BRCA wild type tumors.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2009/0209537 A1
Published
Aug 20, 2009
Filed
Jun 29, 2007
Class
A61K 31/5377
Document BUS 2022/0319704 A1
Published
Oct 6, 2022
Filed
May 6, 2020
Class
G16H 50/20
Claim 1
Document A
Document B
1.1a) identifying the cancer to be a BRCA mutation cancer or a BRCA wild type cancer having a homologous recombination deficiency; and
In some embodiments, to establish a ground truth for the training data, cancer samples with bi-allelic inactivation of one or more genes associated with homologous recombination deficiency (such as BRCA1, BRCA2, ATM, ATR, BAP1, BARD1, BLM, BRIP1, MRE11A, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, or XRCC2) can be labeled as homologous recombination deficient.
B · US 2022/0319704 A1 · ¶ 168
1.2b) administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising (i): an Aurora A inhibitor or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof, and (ii) a PARP inhibitor, or or a pharmaceutically acceptable salt, hydrate, solvate, amorphous solid, or polymorph thereof.
(30) A method for inhibiting Aurora A comprising a step of administering an effective amount of the indazole derivative or the pharmaceutically acceptable salt thereof described in any one of (1) to (15).
A · US 2009/0209537 A1 · ¶ 49
In some embodiments, the regimen comprises administration of an effective dose of a PARP inhibitor such as niraparib daily until disease progression or unacceptable toxicity occurs.
B · US 2022/0319704 A1 · ¶ 202

An empty cell means only that no passage was reproduced there.

Statements in these documents
These abnormalities in the mitotic kinases are considered to be one of the causes of chromosome instability characteristic of many cancer cells and thus Aurora inhibitors are considered to be useful as therapeutic agents for a variety of cancers such as colon cancer.
A · US 2009/0209537 A1 · ¶ 2
An object of the present invention is to provide an Aurora inhibitor which comprises, as an active ingredient, an indazole derivative or a pharmaceutically acceptable salt thereof and the like.
A · US 2009/0209537 A1 · ¶ 18
Thus, it can be useful to determine or diagnose whether or not a cancer is HRD for treatment planning; for example, treating an individual with a cancer that is characterized or identified or diagnosed as HRD with a PARP inhibitor or other drug substance that is effective because the cancer is HRD.
B · US 2022/0319704 A1 · ¶ 5
However, relying on mutational sequencing analysis to characterize a cancer as homologous recombination deficient can result in delayed treatment or may be under-inclusive in detecting HRD cancers.
B · US 2022/0319704 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355172 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355172/, SHA-256 0e065beb74357ee588339c3461234c8cd848b675b39f6b347764b9887890836c
First published
Permanent addresshttps://patent.fyi/US20260355172/
Content fingerprint (SHA-256)0e065beb74357ee588339c3461234c8cd848b675b39f6b347764b9887890836c
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi